The implication is that, historically, outcomes measures in clinical research (eg, blood pressure, survival, laboratory test results) do not reflect outcomes that matter to stakeholders in that research (eg, patients, clinicians, researchers). 2 Outcomes that matter may reflect more subjective states of patient well-being, experience, or behavior that are not directly observable by another person. Patientreported outcomes (PROs), defined as "outcome [s] reported directly by patients themselves and not interpreted by an observer," 3 have been widely adopted as one way to assess outcomes that matter to PCOR stakeholders. 4 Hence, PCOR protocols often call for the measurement of PROs, and for stakeholders in that research to be engaged in making decisions about which PRO to measure and how to measure it (ie, PRO selection), and how to systematically collect PRO measures from the population of interest (ie, PRO measure implementation). [5] [6] [7] [8] In practice-based research, PRO measures are often meant to be implemented in the clinical practice setting, administered to patients in the context of their care. Thus, both the researchers and those interfacing with clinical practice (eg, patients, clinicians, staff, operations, and practice and organizational leadership) are stakeholders whose diverse perspectives should be considered in a PRO selection and implementation effort. In addition to increasing relevance and interest, engaging both researchers and clinical practice stakeholders in PRO selection and implementation may reduce barriers to implementation and enhance data quality and value. 5,8 -15 While there are several frameworks and methods for stakeholder engagement, 15 there is currently limited literature on the application of these methods in PRO selection and implementation. The objective of this article is to describe the application of a stakeholder engagement methodology to PRO implementation in clinical practices involved in a practice-based research network (PBRN). The PRO measures implemented as a result of this effort are then intended to be used as outcomes data for our broader PCOR efforts concerning the effects of care in a patient-centered medical home (PCMH) on outcomes for a cohort of patients with hypertension and/or hyperlipidemia.
PRO measures and Uses
PROs are often measured using questionnaires administered directly to patients, either verbally or in a written or electronic survey. 16 PRO measures include measures of a patient's health status, ability to function, symptoms, quality of life, or experience of care. 17 Information provided by PRO measures can be used to inform individual patient care, population surveillance, adverse event monitoring, quality improvement, performance monitoring, and research. 18, 19 In clinical practice, uses of PRO measures include monitoring symptoms, disease progress, and responsiveness to treatment; augmenting patientprovider communication and shared decision making; and providing feedback to health care professionals as a performance measure. 6,20 -23 Systematic reviews of the effects of implementing PRO measures in clinical practice show potential for improved care processes (eg, patient-provider communication, diagnosis), whereas findings related to health outcomes (eg, patient health and well-being, satisfaction) are mixed. 6, 7, 22, 24, 25 PRO Implementation While PRO measures have value for both clinical and research purposes, there are scientific and logistical barriers to efficient and effective implementation and use of the results-a longstanding problem in practice-based data collection efforts. 26, 27 Beyond common concerns such as data validity and quality (eg, data completeness), 28 -30 researchers and clinicians may have conflicting priorities that make it difficult to collect PRO measures to serve research and clinical purposes. The most valid measures and rigorous data collection methods from a research perspective may not have sufficient clinical, quality improvement, or operational value; as such, practices may not be able to justify the time required to modify workflows, implement data collection tools, and train personnel. Yet, when individual practices implement PRO measures in ways that best fit their environment and workflow (a priority for clinicians), this introduces practicelevel inconsistencies in how data are collected and possible selection bias, creating threats to validity from a research perspective. 31 Thus PRO implementation in clinical practice may benefit from stakeholder engagement methods that facilitate alignment of research and clinical practice stakeholder perspectives.
Stakeholder Engagement Methods
Deverka and colleagues 15 define stakeholder engagement as "An iterative process of actively soliciting the knowledge, experience, judgment and val-ues of individuals selected to represent a broad range of direct interests in a particular issue, for the dual purposes of: 1) Creating a shared understanding; and 2) Making relevant, transparent and effective decisions." Early steps in engagement include identifying relevant stakeholders, establishing roles and responsibilities of the various stakeholders, and selecting an engagement strategy.
14 This engagement strategy should build trust, garner the commitment of the stakeholders and researchers, and elicit and align diverse perspectives. Stakeholder engagement methods go beyond elicitation of the perspectives of stakeholders-as exemplified by focus group or key informant interview methods-to encompass full participation and collaboration. 15, 32 Through such collaboration, research and clinical stakeholders seek to select PRO measures that are "actionable, efficient, interpretable, obligatory, and user-friendly," aspects that are thought to be key features of successful PRO implementation. 33 Thus we expected that stakeholder engagement strategies would allow us to select and implement PRO measures in a way that met both research and clinical practice needs.
Methods

Setting
The Scalable Architecture for Federated Translational Inquiries Network (SAFTINet) is a multistate, safety-net focused PBRN. PBRNs are built on a foundation of stakeholder engagement and are a vital laboratory for real-world research. 34, 35 SAFTINet is also a distributed data network, 36 with locally controlled databases of administrative, clinical, Medicaid claims and enrollment, and PRO data-including the PRO data gathered through the stakeholder engagement process described here-which can be used for a broad range of research, quality improvement, and care delivery purposes. 37 At the time of this project, SAFTINet had 4 partnering clinical practice organizations, with 54 participating primary care practices (federally qualified health centers or federally qualified health center "look-alikes") in Colorado and Tennessee, caring for approximately 260,000 unique patients per year. An estimated 65,000 patients had hypertension and 39,000 patients had hyperlipidemia. Specialties include family medicine, internal medicine, pediatrics, and behavioral health. Practices range in location from urban to rural; all have an electronic health record (EHR).
Stakeholder Engagement Methods
Existing models and frameworks for stakeholder engagement in PCOR include a taxonomy of stakeholder engagement proposed by Concannon and colleagues, 8 and a conceptual model for stakeholder engagement from Deverka and colleagues. 15 Both suggest that the first step is identifying relevant stakeholders, which may include researchers, clinicians, health care providers (the institutions), and patients, among others. According to the analytic-deliberative model for stakeholder engagement presented by Deverka et al, the stakeholders then undertake a process of gathering and analyzing the evidence (the inputs, which include stakeholder values, experience, and review of the literature), deliberating (the methods for combining evidence), and decision making (the decisions, including topic generation, study designs, and implementation strategies). Although this model was published after our work was completed, it closely mirrors our process and we refer to it here as an organizing framework.
Identifying Relevant Stakeholders
The 7P stakeholder engagement framework highlights 7 stakeholder groups to engage in developing and implementing research protocols: patients, providers, "principal investigators" (ie, researchers), policymakers, product makers, payers, and purchasers.
2 Our network's first research protocols were broadly concerned with studying the effects of health care delivery models (eg, the PCMH) on chronic disease control. While all "7Ps" of stakeholder groups are relevant to this research, we chose to focus primarily on providers and researchers for our first attempt at stakeholder engagement as a nascent PBRN (we have since engaged patients, payers, policymakers, product makers, and purchasers in our research).
The stakeholder group labeled "providers" is a broad category that includes not just the clinicians themselves but also others who work for clinical practice organizations. This includes nursing staff, medical assistants, quality improvement teams, health information technology staff, and clinical operations and administration personnel. Upon recruitment to SAFTINet, each clinical practice organization partner named an internal site lead (typically someone in a leadership position, such as a clinical director, funded at 0.10 full-time equivalent (FTE) under a subcontract of our infrastructure development grant) and a site coordinator (typically someone with mas-ter's-or doctoral-level training in a clinical or public health-related field; funded at 0.20 FTE) to oversee and manage the scope of work required to implement the network infrastructure and research protocols (work much broader than that required to undertake the activities described in this article). The site leads each were asked to identify a person in their organization who could represent the clinical practice stakeholder perspective in developing research protocols, then serve as a champion for implementing the research protocols within their organization (also supported at 0.10 FTE by our grant). The selected "clinical practice representatives" were typically clinicians or other doctoral-trained individuals with interests in health services research or quality improvement; they were often those directly involved in internal PCMH implementation and evaluation.
Analysis, Deliberation, and Decision Making
After identifying relevant stakeholders, the next step in stakeholder engagement is to undertake an iterative process of analysis, deliberation, and decision making. 15 We primarily used facilitated group discussions for this process. The partner representatives, along with the site coordinators, several PCOR investigators, the network project manager, and community engagement leads, comprised our "partner engagement community" (PEC), which met twice monthly via Web conference for over 3 years to discuss the developing research protocols, including the process of PRO selection and implementation described in this article (which took place over 10 months of this 3-year period). The community engagement leads, who were jointly affiliated with the American Academy of Family Physicians National Research Network and the DARTNet Institute (http://dartnet.info), coordinated and led the PEC meetings. During these meetings, we identified stakeholder needs, priorities, and concerns; reviewed relevant literature or met with experts to ensure our work was guided by the evidence; proposed and debated options; and ultimately reached a consensus. Detailed agendas and PowerPoint slides were used to organize thinking during PEC meetings; follow-up calls and Emails and meeting summaries highlighting key decisions and next steps were used to communicate plans (especially important when PEC representatives periodically missed the conference calls), and project plans were used to monitor progress. The PEC meetings also helped to foster trust and relationships among the stakeholder representatives, based on mutual respect and understanding.
Between PEC meetings the partner representatives would meet with others in their organization who had a vested interest in whatever topic was currently being discussed to vet options and ideas generated during PEC meetings. They then brought these perspectives back to subsequent PEC meetings to inform decision making. For instance, they would meet with quality improvement teams, individual providers in participating practices, or working groups dedicated to certain health conditions (eg, asthma, hypertension). Similarly, the researchers on the PEC would meet with the larger research team to discuss and provide input back to the PEC. We also conducted local partner site pilot testing and iteration before reaching final decisions. While we had an open invitation for partners to bring others from their organization to participate in the PEC discussions, this rarely if ever occurred because of busy schedules.
Implementation Planning
The clinical partner representatives served as liaisons between the PEC and their local sites, and took responsibility for local decision making regarding specific implementation strategies. We provided a structured PRO planning worksheet to guide these local decision-making processes (see Online Appendix). The PRO planning worksheet was designed for this project based on published recommendations from the International Society of Quality of Life (ISOQOL). 38 The ISOQOL "User's Guide to Implementing Patient-Reported Outcomes Assessment in Clinical Practice" articulates 9 questions to be answered before implementation. 39 We identified 3 additional implementation decisions specific to our objectives, which were necessary because of the scale of the project (54 practices) and the need to integrate the data into the SAFTINet databases, which are Observational Medical Outcomes Partnership common data model version 4 schemas (http://OHDSI.org), using a standardized data format to support interoperability. We addressed these decisions in 3 high-level steps, as shown in Table 1 . Our overarching goals were to (1) collect data of sufficient scale and quality that it could be used for rigorous and relevant research, (2) improve care for patients at risk for cardiovascular disease, and (3) implement the data collection in a feasible, minimally disruptive, and sustainable manner.
Implementation Step 1: Determine PRO Content and Select a Measurement Tool
PRO data collection goals from the researcher and clinical partner perspectives are listed in Table 2 . The specific context for the PRO implementation work pertained to our research on the effects of receiving care in a PCMH on outcomes for patients with increased cardiovascular risk as a result of hypertension and/or hyperlipidemia. The types of outcomes considered by the group to be relevant to this research context included general health status, patient activation, medication adherence, cardiovascular risk perception, readiness for change, and self-efficacy. We ultimately agreed on medication adherence and barriers to medication adherence as the content area. Notably, medication adherence is (1) consistent with existing clinical partner reporting requirements, (2) an important factor in reducing cardiovascular risk, 40, 41 and (3) potentially influenced by receiving care in a PCMH. 42, 43 In general, attributes of appropriate instruments for measuring PROs include consistency with the conceptual and measurement model for the construct of interest, reliability, validity, ability to detect change, ease of interpretation of the results, low administrative and respondent burden, and existence of cultural and language adaptations and translations. 44 Among the existing brief, validated instruments for medication adherence, 45 we selected a 1-item instrument developed by Gehi and colleagues 46 because of its simplicity and discriminant and face validity. This tool asks respondents to • Relevant to patients with condition of interest (eg, hypertension and hyperlipidemia)
• Align with the clinical partners' current reporting requirements and quality improvement initiatives, such as PCMH and MU • Potentially influenced by the care in a PCMH
• Brief (Յ4 items), valid measure exists in both English and Spanish and at an appropriate reading level • Valid and reliable measure exists
• Is of utility to the providers (ie, related to a common patient issue, amenable to intervention) • Content should not be redundant with existing data sources (eg, the EHR)
• Informs day-to-day interactions with patients EHR, electronic health record; MU, meaningful use; PCMH, patient-centered medical home.
indicate how often in the last month they had taken their medication as prescribed. We slightly modified the instructions to state "as instructed" rather than "as prescribed," to include over-the-counter as well as prescription medications. We adapted an existing, validated medication adherence barriers checklist at the request of the clinicians and practice representatives, focusing on barriers that are amenable to intervention and commonly encountered in clinical settings. 47 The tool was translated into Spanish by a certified translator.
Before full-scale implementation, 3 of the clinical practice representatives asked 1 to 2 clinicians in their practices to pilot-test the tool's readability and clinical utility during real clinical encounters over the course of 2 weeks. The clinical practice representatives reported back to the PEC that the barriers question helped to engage patients in a conversation about barriers to medication adherence, which the clinician pilot-testers considered to be clinically useful. To support evaluation of the tool's utility, we added 2 items to assess the frequency of such conversations. After 2 more weeks of pilot testing, with no further suggestions, we deemed the tool appropriate for full-scale implementation. The final, single-item medication adherence measure and barriers checklist was referred to as the Medication Adherence Survey (MAS).
Implementation Step 2: Establish Local Implementation Plans
Using our PRO planning worksheet, each of the clinical partner organizations established local implementation plans, considering existing workflow, personnel, resources, structures, and processes, and determined the best way in which a new PRO measure could be integrated into their practices (Table 3) . Each clinical partner representative separately convened appropriate others in their organizations to discuss and complete the worksheet based on what they expected would work best in their practices. (Note that those "appropriate others" varied by organization, ranging from organization-level quality improvement teams or working groups tasked with quality improvement in cardiovascular risk reduction, to the collective of primary care clinicians within the organization). After this local decision-making process occurred, members of each clinical partner organization reviewed their plan with members of the central research team, the feasibility of the plan was discussed, and revisions based on input from both researchers and clinicians were made.
To optimize response rates, data quality, and sustainability, we allowed for flexibility across partner organizations. The timelines for implementation varied across organizations, as PRO implementation needed to be in sync with other planned organizational activities (eg, EHR upgrades). We prioritized consistency across partner organizations in terms of (1) patients targeted, (2) frequency of administration, and (3) the format for the structured capture of results (ie, discrete fields for variable labels and values). Table 3 describes the implementation plans made by the 4 participating clinical organizations and the preferences and recommendations from the research team; each section of the table reflects a major section of the PRO planning worksheet.
Implementation Step 3: Implementation and Evaluation of the PRO measure
Each of the clinical partner representatives worked with his or her respective practices to implement, evaluate, and adapt their PRO data collection processes according to plan and using the internal resources at their disposal. The network project manager and the community engagement leads provided high-level project management over the implementation process using project management tools, such as project plans and regular check-in calls with each site coordinator. Implementation was an iterative process, akin to continuous quality improvement, including auditing the implementation processes, following up with providers to ensure consistent data collection, and addressing any barriers and concerns about impact on workflow, patient satisfaction, and quality of care. Partners documented in their planning worksheets any changes over time to their data collection processes so that we could maintain a record of what changes occurred and when.
We report on the approach to and results of the planning and implementation process based on detailed notes from conference calls and team meetings, project plans, reports from clinical partners showing the total number of surveys administered at each participating practice, slide presentations, and E-mails from throughout the process. These records were used to ensure we accurately described the process and numbers of surveys collected, and to summarize the lessons learned, which 
Results
Stakeholder meetings began in December 2011, and we reached consensus on implementation plans by September 2012. The mutually agreed upon start date for use of the MAS was January 1, 2013. Each partner's local site coordinator was tasked with coordinating execution of the plan, training staff, monitoring progress, and assessing and addressing barriers to the implementation and use of the survey. Site coordinators reported monthly to the project manager the number of surveys collected at each participating practice. Given the focus on adult patients, 45 of the 53 network primary care practices were expected to participate in this PRO implementation (8 were pediatrics-only practices). Note that organization 3 ended up implementing the MAS in all practices and with all ages, including their 3 pediatrics-only practices, since the MAS was expected to be useful for the care of children taking medications for chronic conditions such as attention deficit hyperactivity disorder or asthma. Because this was unique to organization 3 and not relevant to our PCOR protocol, the numbers reported herein do not include surveys administered to those under age 18 years. Initial adoption of the MAS was slow. After 5 months, 22 of 45 practices (49%) had adopted the MAS (ie, collected at least 1 survey). Common barriers to implementation cited by partners included competing organizational priorities and workflow changes. At that time we discussed these challenges as a group and opted to adopt a benchmark. Each practice would attempt to collect at least 25 surveys by the end of the grant in September 2013. This 25-survey benchmark was based on a recommendation from the study biostatistician, who indicated that 25 surveys per practice (the unit of analysis in the multilevel models specified in our PCOR protocol) would provide adequate power for testing our primary hypothesis (ie, that patients receiving care in a PCMH have higher medication adherence than those who do not). By the end of September, 4 months later, 40 of 45 practices (89%) had implemented the MAS and collected a total of 3247 surveys, an average of 72 per practice (median, 30 surveys; range, 0 -416 surveys). Among the practices, 58% (26 of 45) met the 25-survey benchmark. The distribution of survey totals across practices and organizations is shown in Table 4 . Of note, the 22 practices that had already adopted the MAS at the time the benchmark was imposed outpaced those who had not yet adopted the MAS (mean ϭ 119 surveys; median ϭ 91 surveys). Conversely, the 23 practices that had not yet adopted the MAS approached the 25-survey benchmark and little more by the end of the project (mean ϭ 27 surveys; median ϭ 23 surveys). Thus, a benchmark seems to be helpful for late adopters. 
Lessons Learned
At a PEC meeting clinical practice representatives were asked to reflect on barriers and facilitators to implementation of the MAS across their practices. Partners reported that the following factors facilitated implementation of the MAS in clinical practice: the presence of an established EHR with readily modifiable templates (a critical factor present in organizations 1, 3, and 4, but not 2); the availability of care coordinators to facilitate data collection, interpretation, and triage (present in organization 1); audit and feedback reports; established tools and structures and associated workflows in which the MAS could be integrated (eg, health risk appraisals, hypertension-specific visits; present in organizations 3 and 4); and engaged leadership and quality improvement teams. The clinical practice stakeholders reported several challenges during this process. A major challenge was that maintaining momentum can be difficult when there is staff turnover, requiring additional training and reorientation to the project. To the extent that the data collection can be integrated into standard workflows and processes of care in which new staff will be trained, this issue could be mitigated. Organization 2 specifically cited the lack of available incentives to encourage practice staff and providers to administer the MAS as a barrier. Organization 1 cited lack of prior experience with practice-based research as a challenge (all other organizations have been involved with practice-based research for Ͼ10 years). Organization 2 cited competing priorities as a major barrier, mainly a system-wide effort to implement a new EHR, which prevented the MAS from being incorporated into EHR templates as was done at the other organizations. In addition, as described in the quality improvement and practice transformation literature, 48 engaged leadership and a willing champion within each individual practice (eg, quality improvement leader or office manager) helped to maintain momentum, to demonstrate the value of the data for improving quality of care, and to provide audit and feedback to providers and staff. Practices lacking their own local champion (even with engaged leadership at the organization level) were thought to have struggled the most with implementation of the MAS. This approach to engagement required significant compromise and investment of effort from all parties. The researchers had to tolerate the lack of fidelity to a specific data collection protocol, variability across practices in commitment to the work and its implementation, and a prolonged rollout period. Even with a considerable amount of financial support from our infrastructure grant, the clinical organizations had to commit considerable time and effort to discussion and planning, and then invest internal resources in a full-scale implementation of the PRO. Given that their highest priority was providing care to patients, this investment was at times difficult to justify. We estimate this work required approximately 2000 person-hours for the planning ([5 people ϫ 100 hours each] ϩ ]10 people ϫ 60 hours each]) and coordination of local site testing and implementation (4 organizations ϫ 2-3 people per organizationϫ 80 hours each).
Ultimately, the clinical partner stakeholders perceived the MAS as having marginal clinical utility; although the barriers checklist at times drove conversations with patients, the single-item adherence measure was perceived as invalid because most patients reported taking their medications exactly as instructed Ͼ90% of the time. Although our stakeholder engagement process was designed to promote sustainable data collection, most SAFTINet practices elected to discontinue use of the MAS at the project's end, primarily because of the desire to minimize the data collection burden to patients and providers.
Discussion
In this article we describe our method of engaging researchers and clinical practice stakeholders in the implementation of PROs relevant to the care of patients with hypertension and/or hyperlipidemia. We undertook this approach with the expectation that aligning research and clinical practice stakeholder perspectives would yield high-quality, complete, clinically useful, and sustainable data collection processes. Our process mirrored the analytic-deliberative model of stakeholder engagement developed by Deverka and colleagues, 15 such that stakeholders analyzed inputs (stakeholder values, personal experience, and research evidence), deliberated using facilitated discussions, and decided on implementation strategies using planning worksheets informed by the ISOQOL User Guide. 39 Our approach to decision making and implementation can be likened to a cascading hub-andspokes model (Figure 1 ). In summary, at the hub (the PEC), the site coordinator and clinical practice representative from each provider organization met with the research and governance personnel for high-level analysis, deliberation, and decision making. These representatives then convened separately with others in their local organizations and individual clinical practices to again analyze, deliberate, and make more specific, context-appropriate decisions locally, which were communicated back to the hub. The clinical practice representatives and site coordinators were then responsible for managing local implementation of decisions, including determining which specific individuals would take on various roles and responsibilities within the organization and within each practice in the organization.
We learned several lessons about the utility of a stakeholder engagement approach to PRO selection and implementation. Using this approach, we successfully selected and implemented PROs that met the needs of both researchers and clinical practice stakeholders, although there was only a loosely defined protocol, and tolerance for flexibility and adaptations across organizations was required. While resource intensive, a notable benefit of this approach was that clinical partners were willing to coordinate adoption of PRO measures across all primary care practices in their organizations. Another benefit of an approach in which PRO measures are implemented within the context of clinical care and quality improvement (ie, not just for research purposes, but rather to support clinical decision making at the patient level) was that the traditional research concept of subject recruitment did not apply. Thus our institutional review boards waived informed consent (comparable to secondary use of electronic health records data), which can be a critical logistic barrier.
There are limitations to what stakeholder engagement can achieve, however. We expected that engaging clinical practice stakeholders would enhance the selected PRO measure's clinical utility (informs clinical decision making) and sustainability (use of the PRO measure continues after the study period ends). Ultimately, the clinical utility and sustainability of the MAS was predicated on the perceived performance characteristics of the MAS in practice. Key PRO performance characteristic constructs include psychometric soundness, person-centered, meaningful, amenable to change, and feasible to implement. 49 Unfortunately, the clinical practice stakeholders did not perceive the MAS as valid because an unexpectedly large majority of patients reportedly indicated perfect medication adherence. The barriers checklist seemed to have the greatest utility from a clinical practice perspective. The finding that asking patients about barriers served as an entrée to a conversation about medication regimens is consistent with a proposed framework for evaluating the effects of using PRO measures to support chronic illness care. 50 The low perceived validity of the MAS may have been due to our slight modifications to the measure by Gehi et al, 46 thus invalidating the previously established scale. Alternatively, it may be that a broad measure of general medication adherence (ie, not specific to a particular medication) is unclear or unacceptable to patients. Furthermore, while the measure by Gehi et al had been validated in a research context, it was not, to our knowledge, tested in a real-world clinical practice context. Finally, it may be that medication adherence is not a suitable PRO for patients with increased cardiovascular risk. In the time since we conducted this work, the American Heart Association released a statement indicating that appropriate PRO measures for assessing cardiovascular health may include patient-reported health status with respect to symptoms (burden of angina, dyspnea, depression), functional status, and health-related quality of life-topics that may resonate with patients as meaningful to their quality of life.
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Limitations
Our experiences with this approach may not generalize beyond this group of partners or beyond this Figure 1. Cascading hub-and-spokes model of implementation. IT, information technology; PCOR, patient-centered outcomes research; QI, quality improvement. particular clinical context (ie, PROs for a cohort of patients with hypertension/hyperlipidemia); the timeline may have been much shorter and the level of interest at the practice level may have been greater if there was a well-established recommendation for a PRO for this cohort. While we considered researcher and clinical practice stakeholder perspectives in PRO selection and implementation, we did not engage patients beyond asking for their feedback on the readability of the survey during pilot testing. By engaging patients, we might have selected a more valid and reliable measure of adherence, or we might have selected a different PRO altogether. We did not formally evaluate data collection using this stakeholder engagement approach versus another approach (or no stakeholder engagement at all); thus we can make no conclusions regarding the relative effectiveness of this approach. However, the clinical partners would not have considered undertaking this broad PRO implementation effort if the researchers had not approached it from a collaborative perspective. In that respect, we are confident that the adoption of PROs at the organizational level was greater because of this approach.
Finally, this description of our collective experience as researchers and clinical practice representatives is not research or a formal evaluation of our process, and no qualitative analysis was conducted. Rather, this is a methods and reflection article, coauthored by both the researcher and clinical stakeholder representatives.
Implications and Future Research
Since the advent of the EHR, there has been a nearly overwhelming increase in the amount of data that providers are expected to collect and document in structured fields and checkboxes in the EHR. 52, 53 When adding PRO measures to this data collection burden, the value gained by a PRO is weighed in the context of the effort required to collect and interpret the data. Additional PRO data collection will eventually become untenable for both patients and care providers. Potential solutions include targeting data collection to those patients for whom the data are most relevant (thus reducing the total burden to any individual patient); establishing systems that allow for a larger involvement of the care team in making clinically relevant information available to the clinical provider at the point of care; adopting the use of patient portals, kiosks, and smartphone applications to collect information before the visit; and weeding out data collection that does not prove to be useful. Therefore, further work is needed to identify methods and infrastructure that can be useful for rapid adoption of PROs for research purposes.
